Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions

Not Applicable

Completed

• Conditions: Coronary Artery Disease
• Interventions: Device: Cilostazol eluting stent system (CES-1)

• Registration Number: NCT03189641
• Lead Sponsor: JIMRO Co., Ltd.

Brief Summary

The purpose of the this trial is to evaluate the clinical safety and efficacy of Cilostazol eluting stent system (CES-1) for the treatment of single de novo lesions in native coronary arteries.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-05-31
• Study First Submitted: 2017-06-13
• Study First Submitted QC: 2017-06-15
• Study First Posted: 2017-06-16
• Primary Completion: 2020-03-27
• Study Completion: 2024-07-26
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-11
• Last Update Posted: 2025-03-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

<Clinical selection criteria>

1. Patients who have provided written informed consent.
2. Patients who have evidence of myocardial ischemia confirmed by subjective symptoms (chest pain etc.), ST change in the electrocardiogram or objective findings.
3. Patients who are at least 20 years old.

<Angiographic selection criteria>

1. Single de novo lesion in native coronary arteries
2. Target vessel diameter is 2.75 mm to 3.25 mm.
3. TIMI flow is 2 or more.
4. Angiographic percent diameter stenosis (by visual estimation) is 75% or more in AHA classification

Exclusion Criteria

<Clinical exclusion criteria>

1. Acute myocardial infarction Patients whose CK-MB or troponin exceeds the facility reference upper limit and have at least one of the following is confirmed are excluded as acute myocardial infarction.

   • Ischemic symptoms and Electrocardiographic findings showing continuous ischemia (eg, ST segment elevation or depression above 1 mm in contiguous leads, or the appearance of a new left bundle branch block).
   • Pathological Q waves on electrocardiogram
   • Myocardial necrotic focus or wall motion abnormality newly confirmed in diagnostic imaging

2. Patients who cannot be given emergency coronary artery bypass grafting (CABG).

3. Patients who cannot be administered antiplatelet drugs. The following cases are conceivable.

   • Significant intracranial hemorrhage, gastrointestinal bleeding, urinary tract hemorrhage etc. within the last 6 months
   • Surgical operation is planned that requires discontinuation of DAPT after the procedure
   • Anticoagulation therapy is underway and the risk of bleeding is high

4. Bleeding tendency due to hemorrhagic diathesis or blood coagulation disorder.

5. Left ventricular ejection fraction (LVEF) is less than 30% within 30 days before the trial registration.

6. Renal dysfunction (Creatinine value exceeds 2.0 mg/dl or in case artificial dialysis).

7. Allergy to cobalt chrome alloy or contrast agent.

8. Patients who are participating in or will planning to participate in other clinical studies that may have clinical implications for the evaluation of this trial.

9. Patients who are pregnant or breast feeding.

10. Patients who are taking Cilostazol.

11. In cases where the Investigator determines that the patient's participation in the trial is inappropriate.

<Angiographic exclusion criteria>

1. Lesion in left main coronary trunk
2. Lesion within 5 mm from the ostium right coronary artery
3. Lesion within 5 mm from the ostium left anterior descending/the ostium left circumflex branch
4. Bifurcation lesion
5. Within 1 year after implementing PCI on the target vessel or its branch
6. There are other lesions that require PCI at the time of the procedure
7. Type C of ACC / AHA classification

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Cilostazol eluting stent system (CES-1)	Cilostazol eluting stent system (CES-1)	-

Primary Outcome Measures

Name	Time	Method
In-segment late lumen loss as measured by quantitative coronary angiography (QCA)	9 months

Secondary Outcome Measures

Name	Time	Method
%Incomplete stent apposition (%ISA) as measured by OCT/OFDI	9 Months
Device Success rate	Immediate post-procedure	Device success is defined as successfully placement of the investigational stent at the target lesion, and attainment of less than 50% residual stenosis at the end of stenting.
Target Vessel Failure (TVF)	9 Months
Stent thrombosis	9 Months
Patient Oriented Composite End point (POCE)	9 Months	POCE: All cause death, all myocardial infarction, or all revascularization with ischemia
%Volume obstruction as measured by OCT/OFDI	9 Months
%Covered strut as measured by OCT/OFDI	9 Months
Procedure success rate	At the time of hospital discharge, expected 1or 2 days after of procedure	Procedure success is defined as attainment of less than 50% residual stenosis at the end of stenting and no major adverse cardiac events (death (excluding cases obviously caused by other than coronary ischemia), myocardial infarction, target lesion revascularization (TLR)) during hospitalization.
In-stent and in-segment %diameter stenosis (%DS) as measured by QCA	9 Months
In-stent and in-segment %Angiographic Binary Restenosis (%ABR)	9 Months
Neointima volume as measured by OCT/OFDI	9 Months
Target Lesion Failure (TLF)	9 Months

Trial Locations

Locations (6)

Mitsui Memorial Hospital; 🇯🇵 Chiyoda, Tokyo, Japan

Kitasato University Hospital; 🇯🇵 Sagamihara, Kanagawa, Japan

Tokai University Hospital; 🇯🇵 Isehara, Kanagawa, Japan

Saiseikai Yokohamashi Tobu Hospital; 🇯🇵 Yokohama, Kanagawa, Japan

Showa University Fujigaoka Hospital; 🇯🇵 Yokohama, Kanagawa, Japan

Teikyo University Hospital; 🇯🇵 Itabashi, Tokyo, Japan